THERAPY DOSSIER · th-20c1d9dca31a

7ND-MSCs (mesenchymal stem cells transduced with dominant-negative CCL2 inhibitor 7ND)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21741938 ↗2011Reported benefit

Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage.

MouseChemical/toxinC57BL/6MaleInjection (intravenous)

Model: Bleomycin-induced lung injury (ARDS model)

MSCs engineered to express the dominant-negative CCL2 inhibitor 7ND attenuated bleomycin-induced lung damage and improved survival in mice.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…